ImmunoGen Inc. (IMGN)

Oncology Corporate Profile

Stock Performance


HQ Location

830 Winter Street
Waltham, MA 2451

Company Description

ImmunoGen develops targeted anticancer therapeutics. ImmunoGen's proprietary Tumor-Activated Prodrug (TAP) technology and strong antibody expertise form the basis for their development of their own products as well as partnerships with other companies.


Brand Generic Indication
Kadcyla®ado-trastuzumab emtansineKadcyla® is a HER2 targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination.

Patients should have either:
• Received prior therapy for metastatic disease, or

• Developed disease recurrence during or within six months of completing adjuvant therapy.
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
isatuximabtherapeutic antibodyMultiple MyelomaIIISanofi
Kadcyla® / ado-trastuzumab emtansine / T-DM1antibody drug conjugate1st line metastatic Breast cancer (HER2+)IIIGenentech / Roche
Kadcyla® / ado-trastuzumab emtansine / T-DM1antibody drug conjugate3rd line metastatic Breast cancer (HER2+)IIIGenentech / Roche
SAR3419anti-CD19 monoclonal antibody (maytansin-loaded)B-cell Acute Lymphocytic Leukemia (B-ALL)IISanofi
coltuximab ravtansine / SAR3419antibody drug conjugate (TAP compound)Diffuse large B-cell Lymphoma (DLBCL)IISanofi
anetumab ravtansineantibody drug conjugateMesotheliomaIIBayer
indatuximab ravtansineantibody drug conjugateMultiple MyelomaII
IMGN529antibody drug conjugate (TAP compound)Non-Hodgkin's Lymphoma (NHL)II
lorvotuzumab mertansine / IMGN901antibody drug conjugate (TAP compound)Small Cell Lung Cancer (SCLC)II
Kadcyla® / ado-trastuzumab emtansine / T-DM1antibody drug conjugate1st line metastatic Gastric cancerIIGenentech / Roche
IMGN779antibody drug conjugateAcute Myelogenous Leukemia (AML)I
indatuximab ravtansineantibody drug conjugateBladder cancerIBiotest
indatuximab ravtansineantibody drug conjugateBreast cancerIBiotest
mirvetuximab soravtansine / IMGN853folate receptor alpha (FR®)-targeting ADCEndometrial cancerI
BT-062antibody drug conjugate (TAP compound)Multiple MyelomaI
lorvotuzumab mertansine / IMGN901antibody drug conjugate (TAP compound)Multiple MyelomaI
lorvotuzumab mertansine / IMGN901antibody drug conjugate (TAP compound)Ovarian cancerI
mirvetuximab soravtansine / IMGN853FOLR1-targeting antibodyOvarian cancerI
mirvetuximab soravtansine (+ bevacizumab) / IMGN853folate receptor alpha (FR®)-targeting ADCOvarian cancerI
mirvetuximab soravtansine (+ carboplatin) / IMGN853folate receptor alpha (FR®)-targeting ADCOvarian cancerI
mirvetuximab soravtansine (+ pegylated liposomal doxorubicin) / IMGN853folate receptor alpha (FR®)-targeting ADCOvarian cancerI
mirvetuximab soravtansine (+ pembrolizumab) / IMGN853folate receptor alpha (FR®)-targeting ADCOvarian cancerI
mirvetuximab soravtansine / IMGN853FOLR1-targeting antibodyVarious cancer typesI
BAY 94-9343anti-mesothelin antibody-drug conjugateVarious cancer typesIBayer, Immunogen
SAR650984anti-CD38 monoclonal antibody (naked)Various cancer typesISanofi
AVE1642anti-IGF-1R monoclonal antibody (humanized)Various cancer typesISanofi
IMGN388antibody drug conjugate (TAP compound)Various cancer typesI
lorvotuzumab mertansine / IMGN901antibody drug conjugate (TAP compound)Various cancer typesI
BIIB015antibody drug conjugate (TAP compound)Various cancer typesI
SAR566658antibody drug conjugate (TAP compound)Various cancer typesISanofi
SAR408701antibody drug conjugateVarious cancer typesISanofi
SAR566658antibody drug conjugate (TAP compound)Ovarian cancerPreclinicalSanofi
IMGN289anti-EGFR monoclonal antibodyVarious cancer typesPreclinical
SAR566658antibody drug conjugate (TAP compound)Various cancer typesPreclinicalSanofi

View additional information on product candidates here »


Recent News Headlines

ImmunoGen Reports Efficacy and Safety Data From a 46-Patient Cohort of Mirvetuximab Soravtansine in FRa-Positive Ovarian Cancer

5/19/2016 05:32 pm

(Stockwatch) May 18, 2016 - ImmunoGen, Inc. today reported the clinical data from a 46-patient Phase 1 cohort evaluating the efficacy and safety of mirvetuximab soravtansine as single-agent therapy for platinum-resistant, folate receptor alpha (FRa)-positive ovarian cancer.

ImmunoGen Hires Former Shire, Genzyme Exec As New CEO

4/27/2016 05:12 pm

(Boston Business Journal/BioFlash blog) Apr 26, 2016 - One of the area’s largest developers of cancer drugs, ImmunoGen, has named a former Shire and Genzyme executive as its new CEO.

ImmunoGen Announces Initiation of Clinical Testing of First-in-Class IMGN779 for Acute Myeloid Leukemia

4/18/2016 04:33 pm

(TheStreet) Apr 18, 2016 - Novel CD33-targeting product candidate is the first antibody-drug conjugate (ADC) to employ an IGN, a new type of cancer-killing agent; Phase 1 study in acute myeloid leukemia (AML) is designed to efficiently inform the IMGN779 development pathway.

Daniel Junius to Retire as President and CEO of ImmunoGen, Inc.

4/5/2016 04:27 pm

(ImmunoGen) Apr 5, 2016 - ImmunoGen, Inc. a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius, age 63, has decided to retire from his positions of President and CEO of the Company.

West Cancer Center Chooses Flatiron Health’s OncoEMR® and OncoAnalytics® to Support High Quality Patient Care

3/1/2016 11:04 am

(Flatiron Health) Mar 1, 2016 — Flatiron Health and West Cancer Center today announced that West Cancer Center selected OncoEMR® and OncoAnalytics® to enhance the delivery of high quality evidence-based care, support participation in alternative payment models and better manage clinical workflows.

Some Heart Drugs And Antibiotics Show Effective In Fighting Cancer

2/9/2016 11:04 am

(University of Montreal News) Feb 9, 2016 - North American researchers have identified drugs that showed promising perspectives in treating cancers, according to a recent study published in Cancer Research.

Here's Why ImmunoGen's CEO Is Psyched for Combo Tests With Keytruda

2/4/2016 06:09 pm

(Boston Business Journal/BioFlash blog) Feb 4, 2016 - ImmunoGen says that in coming months it plans to test its experimental cancer drug in combination with Merck’s drug, Keytruda, after mouse trials done internally at the company — confirmed by academic studies — show the two drugs may multiply each others' effects.

ImmunoGen and Merck Establish Collaboration for Clinical Evaluation of Mirvetuximab Soravtansine in Combination with Keytruda(R) (pembrolizumab) for the Treatment of Ovarian Cancer

2/4/2016 01:33 pm

(ImmunoGen) Feb 4, 2016 - ImmunoGen's mirvetuximab soravtansine folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC) to be assessed in combination with Merck's anti-PD-1 therapy.

ImmunoGen Earns Milestone with Bayer's Initiation of a Phase 2 Clinical Study Designed to Support Anetumab Ravtansine Registration

1/26/2016 05:45 pm

(ImmunoGen) Jan 26, 2016 - ImmunoGen, Inc. today announced the Company earned a milestone payment with Bayer's initiation of a global Phase 2 clinical study designed to support registration of anetumab ravtansine (BAY 94-9343).

ImmunoGen Announces Recent Product Program Advancements and Anticipated 2016 Events in Advance of J.P. Morgan Healthcare Conference

1/11/2016 05:13 pm

(Benzinga) Jan 10, 2016 - ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced recent product program advancements and anticipated 2016 events in advance of the 34th Annual J.P. Morgan Healthcare Conference.

Critical Outcome Technologies Pursues Orphan Drug Designation for COTI-2 Intended to Treat Li-Fraumeni Syndrome

12/2/2015 12:01 pm

(CNNMoney) Dec 2, 2015 - Critical Outcome Technologies Inc. announced today that it submitted an Orphan Drug Application intended for the treatment of Li-Fraumeni Syndrome (LFS) to the U.S. Food and Drug Administration (FDA) for its lead cancer drug candidate, COTI-2.

Led By Biotech Stars, ORIC Nabs $53M To Fight Drug-Resistant Cancer

12/2/2015 12:00 pm

(Xconomy San Francisco) Dec 2, 2015 - Rich Heyman twice made hay developing drugs to treat cancers that depend on hormones to thrive. Now he’s trying it again with a new company markedly different than the previous two.

Guided Therapeutics and FDA Review Team Agree on Path Forward for LuViva® Advanced Cervical Scan PMA Application

12/2/2015 12:00 pm

(Yahoo! Finance) Dec 2, 2015 - Guided Therapeutics, Inc., the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today it believes it has reached a general agreement with the U.S. Food and Drug Administration (FDA) on a plan for submitting an approvable application for the LuViva® Advanced Cervical Scan.

Abcodia Announces Initial U.S. Availability of the ROCA® Test to Aid in the Early Detection of Ovarian Cancer

12/2/2015 12:00 pm

(Abcodia) Dec 2, 2015 - Abcodia Ltd, a clinical stage company engaged in the commercial development of novel tests for the early detection of cancer, announced today the availability of the ROCA® Test for use by physicians in five U.S. states: Arizona, Illinois, Massachusetts, New Jersey and Texas.

Screen-Film Mammography Will Soon be ‘Virtually Obsolete,’ FDA Says

12/2/2015 12:00 pm

(RAPS) Dec 1, 2015 - As quality issues with screen-film mammography continue to crop up, the US Food and Drug Administration (FDA) says facilities are almost done transitioning to full field digital mammography (FFDM) units 15 years after they came into clinical use.

CMS Corrects 2016 Reimbursement Rate for Cologuard®

12/2/2015 12:00 pm

(Yahoo! Finance) Dec 2, 2015 - Exact Sciences Corp. announced that the Centers for Medicare and Medicaid Services (CMS) indicated that it is correcting the 2016 Clinical Laboratory Fee Schedule (CLFS) and will include the reimbursement national limitation amount (NLA) for Cologuard at $493.21.

Preliminary Phase 2 Data Demonstrate Tumor Treating Fields is Safe in Patients with Brain Metastases Originating from Non-Small Cell Lung Cancer

12/2/2015 11:05 am

(TheStreet) Dec 2, 2015 - Preliminary data from COMET, a phase 2 randomized trial sponsored by Novocure, show that the use of Tumor Treating Fields (TTFields) therapy is safe in the treatment of brain metastases originating from non-small cell lung cancer (NSCLC).

Immunovaccine's DPX-Survivac Induces an Immune Response in Diffuse Large B Cell Lymphoma

12/2/2015 11:05 am

(MarketWatch) Dec 2, 2015 - Immunovaccine Inc., a clinical stage vaccine and immunotherapy company, today announced that the initial results from a Phase 2 study demonstrated that DPX-Survivac can induce a strong immune response in diffuse large B cell lymphoma (DLBCL) tumors.

Kite Pharma Initiates the ZUMA-3 Study to Support Registration of KTE-C19 for Relapsed or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) in Adult Subjects

12/2/2015 11:05 am

(Kite Pharma) Dec 2, 2015 - Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous cell therapy (eACT(TM)) products for the treatment of cancer, today announced that it has initiated a phase 1/2 clinical study of KTE-C19 (ZUMA-3) for the treatment of adult patients with r/r ALL.

OncoGenex Announces Phase 3 AFFINITY Trial with Custirsen Continues Following Interim Analyses

12/2/2015 11:05 am

(MarketWatch) Dec 1, 2015 - Final results expected in second half of 2016.

Boehringer Ingelheim and MD Anderson Join Forces To Discover New Treatment Approaches For Pancreatic Cancer

12/2/2015 11:05 am

(MD Anderson) Dec 2, 2015 - Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative medicines for pancreatic ductal adenocarcinoma (PDAC).

In India, IBM's Watson Will Aid Cancer Care Where Doctors Are Scarce

12/2/2015 11:05 am

(Forbes) Dec 2, 2015 - IBM and a large hospital system in India have partnered to diagnose and treat cancer care in a country of 1.2 billion residents who often cannot access oncologists, leaving their diseases undetected and untreated.

Radiotherapy May Help in Node-Positive Prostate Cancer

12/2/2015 11:04 am

(Medscape/Reuters Health) Dec 2, 2015 - Adding prostate and pelvic radiotherapy (RT) to hormone therapy appears to cut relapse rates in men newly diagnosed with high-risk nonmetastatic (M0) node-positive prostate cancer, according to an exploratory analysis by European investigators.

Cancer Patients May Benefit From Mindfulness-Based Therapy

12/2/2015 11:04 am

(Reuters Health) Nov 30, 2015 - Mindfulness-based therapy may help ease anxiety and depression in some patients with cancer, a small research review suggests.

Novartis Presents New Data On Targeted Combination Therapy At SABCS Reinforcing Commitment To Breast Cancer Patients

12/2/2015 11:04 am

(Novartis) Dec 2, 2015 - Novartis will present data that highlight advancements in targeted combination therapy research, and underscore the company's continued commitment to bringing innovative treatments to patients living with advanced breast cancer at the 2015 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), December 8-12.

ImmunoGen Refines Drug Targeting for Ovarian Cancer Patients

11/9/2015 01:08 pm

(TheStreet) Nov 8, 2015 - Ovarian cancer patients with tumors expressing high levels of a specific protein on their surface respond best to treatment with ImmunoGen's "smart bomb" cancer drug.

ImmunoGen, Roche Gastric Cancer Drug Fails Study

10/22/2015 04:42 pm

(Reuters) Oct 22, 2015 - ImmunoGen Inc said the gastric cancer drug it is developing with Roche Holding AG did not meet the main goal in a large study.

How to Know Whether to Believe a Health Study

8/18/2015 12:02 pm

(New York Times/The Upshot) Aug 17, 2015 - One of the chief limitations of randomized trials is that they’re typically focused on narrow populations that meet strict criteria — those most likely to benefit from treatment.

ASCO Updates Guideline for Use of White Blood Cell Growth Factors

7/15/2015 11:04 am

(ASCO) July 13, 2015 - The American Society of Clinical Oncology (ASCO) today issued an update to its 2006 clinical practice guideline on the use of white blood cell growth factors (also known as hematopoietic colony-stimulating factors, CSFs). The agents are given to lower the risk of low white blood cell counts and fever (febrile neutropenia) associated with certain types of chemotherapy.

Vertex Profits Hinge on FDA Approving New Cystic Fibrosis Drug This Week

6/30/2015 12:02 pm

(TheStreet) June 29, 2015 - Vertex Pharmaceuticals is widely expected to win U.S. approval later this week for a new drug which could one day treat almost half of cystic fibrosis patients.

Lipid in Avocados May be Key to Leukemia

6/16/2015 11:05 am

( June 15, 2015 - A molecule derived from avocados targets leukemia stem cells.

ASCO '15: ImmunoGen Finds Redemption in Strong Ovarian Cancer Drug Results

6/1/2015 11:06 pm

(TheStreet) June 1, 2015 - The perception that ImmunoGen can't develop a drug successfully on its own will probably improve Monday when post-ASCO trading kicks in.

ImmunoGen’s Mirvetuximab Soravtansine (IMGN853) Demonstrates Notable Single Agent Activity for Patients with Platinum-Resistant Ovarian Cancer

5/30/2015 11:32 pm

(StreetInsider) May 30, 2015 - ImmunoGen, Inc., a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentation at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting of the first clinical findings in a disease-specific patient population with the Company’s unique, FR-targeting ADC, mirvetuximab soravtansine (abstract #5518).

NCCN Receives $2-Million Funding Commitment from ImmunoGen, Inc. to Study Mirvetuximab Soravtansine for Folate Receptor Alpha-Positive Cancers

5/15/2015 05:59 pm

(NCCN) May 15, 2015 - The NCCN Oncology Research Program (ORP) has received a $2-million grant from ImmunoGen, Inc. to facilitate preclinical and clinical research with mirvetuximab soravtansine for folate receptor alpha-positive cancers at NCCN Member Institutions and their affiliate community hospitals.

ImmunoGen, Inc. Announces Clinical Data Presentations at Upcoming ASCO Annual Meeting

5/14/2015 06:14 pm

(MarketWatch) May 13, 2015 - Presentations to include initial findings with Company’s mirvetuximab soravtansine (IMGN853) for ovarian cancer and results from Roche’s MARIANNE trial with Kadcyla®.

ASCO Launches PracticeNET, a Collaborative Reporting Network for Oncology Practices

5/6/2015 11:05 am

(ASCO) May 6, 2015 - The American Society of Clinical Oncology (ASCO) announced today the launch of PracticeNET, a collaborative network in which practices will share and receive insights to enhance their business operations and quality of care. PracticeNET is the first initiative of ASCO’s newly-formed Clinical Affairs Department.

On Weak Day for Biotech Stocks, ImmunoGen Slides on Setbacks for 2 Experimental Drugs

4/28/2015 05:02 pm

(FoxBusiness/Associated Press) Apr 27, 2015 - Shares of cancer drugmaker ImmunoGen slumped Monday as Wall Street digested two hits to the company's drug development pipeline.

GlobeImmune Announces Opening of Randomized Phase 2 Chordoma Trial at National Cancer Institute

4/22/2015 11:03 am

(NASDAQ) Apr 22, 2015 - GlobeImmune, Inc. today announced that a randomized Phase 2 clinical trial designed to investigate the safety and efficacy of GI-6301 in combination with radiation therapy in patients with chordoma is open for enrollment at the National Cancer Institute (NCI).

AACR, ABC News’ Dr. Richard Besser Use Twitter’s Periscope to Live Stream “Breakthroughs in Cancer Research” From 2015 Annual Meeting

4/22/2015 11:03 am

(AACR) Apr 22, 2015 - The American Association for Cancer Research (AACR) and Richard Besser, MD, ABC News' chief health and medical editor, joined forces Tuesday afternoon on Besser's Twitter chat to share stories, observations, and significant research from the nation's top cancer researchers in conjunction with the AACR Annual Meeting, held April 18 to 22, in Philadelphia.

Seven New Drugs OK'd for NHS Scotland

4/14/2015 12:01 pm

(PharmaTimes [UK]) Apr 13, 2015 - Seven new medicines have been accepted for use by the National Health Service in Scotland, including therapies for leukaemia, lung cancer and multiple sclerosis.